Mark A. Findeis

Mark Findeis has over 20 years of experience in the biopharmaceutical industry, starting and leading projects in areas focused on Alzheimer’s disease and neurodegeneration, and is a well-recognized investigator in the field. Dr. Findeis is a broadly experienced start-up and small company scientist and manager and has established a series of industrial research laboratories and programs that have demonstrated repeated success at achieving technical and business success. As the founder of Satori Pharmaceuticals, Dr. Findeis was instrumental in the raising of seed capital and syndicated venture funding and led a program developing novel gamma-secretase modulators based on derivatives of a plant steroid natural product. Dr. Findeis has particular expertise working at the interface of medicinal chemistry, (glyco)protein structure-function, and drug discovery. Dr. Findeis helped to start TargeTech Incorporated where he developed practical approaches to the use of glycoproteins and glycopeptides for targeted drug delivery. After the acquisition of TargeTech by The Immune Response Corporation, he joined Praecis Pharmaceuticals where he co-directed the program that put the amyloid aggregation inhibitor ApanTM into clinical development and also supported the development program of the LHRH antagonist PlenaxisTM which received FDA approval. Dr. Findeis is a graduate of M.I.T., received his Ph.D. in Chemistry from Harvard University, and was a postdoctoral fellow at The Rockefeller University.